Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect

After teasing a small data slice in May, Boehringer is now sharing more on its Zealand Pharma-partnered obesity prospect, with new data showing nearly 19% weight loss in a phase 2 trial.